US President Donald Trump has announced a 100% tariff on imports of branded and patented pharmaceutical drugs, effective October 1, 2025.
The Republican leader declared on Truth Social:
“Starting October 1st, 2025, we will be imposing a 100 per cent Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America.”
Trump clarified that “IS BUILDING” refers to plants that have either broken ground or are under construction, meaning pharmaceutical firms can avoid tariffs if they establish local manufacturing in the US.
Industries in Trump’s Tariff Net
This announcement comes alongside a series of new import duties, including:
- 50% on kitchen cabinets and bathroom vanities
- 30% on upholstered furniture
- 25% on heavy trucks
Trump argued that these measures are essential for “National Security and other reasons,” linking them to his larger agenda of cutting deficits and boosting domestic manufacturing.
How Could India Be Impacted?
The US is India’s largest pharmaceutical export market.
- In FY 2024, India exported $27.9 billion worth of pharma goods.
- Out of this, 31% ($8.7 billion / ₹77,138 crore) went to the US.
- In the first half of 2025 alone, India exported $3.7 billion worth of pharma products to America.
India supplies:
- 45% of US generic drugs
- 15% of biosimilars used in the US
Major Indian pharma firms dependent on US revenue include:
- Dr Reddy’s Laboratories
- Aurobindo Pharma
- Zydus Lifesciences
- Sun Pharma
- Gland Pharma
These companies earn 30–50% of their revenues from the US market.
The Uncertainty Ahead
While Trump’s tariffs mainly target branded and patented drugs, questions remain:
- Will complex generics and specialty medicines also face higher tariffs?
- Can Indian firms absorb these costs without hurting profitability?
- Will US consumers face higher drug prices and shortages due to reliance on low-cost Indian generics?
Although several large Indian companies already operate manufacturing plants in the US, smaller firms without a local presence could be hit hard.
Bigger Picture
This move comes after Trump already imposed:
- 50% tariffs on Indian imports across categories
- An additional 25% “penalty” for India’s continued purchase of Russian oil
The aggressive tariff strategy highlights Trump’s “America First” economic policy, but it risks sparking tension with key trading partners like India while increasing costs for American consumers.
Conclusion
Trump’s announcement of a 100% tariff on pharmaceutical imports is set to shake up the global drug trade. For India—America’s biggest source of affordable generics—the move could mean billions in lost revenue, disrupted supply chains, and price hikes in the US healthcare system.
With October 1, 2025 approaching, Indian pharma companies may need to accelerate local US investments or explore alternative export markets to mitigate risks.
